Nanobiotix raises €27.2M

Cancer company Nanobiotix S.A. (Euronext:NANO) raised €27.2 million ($31.6 million) on Tuesday through the sale of 1.9 million shares at €14 in a placement. The price is a 22% discount to the company’s close of €17.84 on Monday, when the offering was announced after market hours.

Nanobiotix's NBTXR3 is in the Phase II/III Act.In.Sarc trial to treat soft tissue sarcoma (STS). The compound comprises crystalline nanoparticles of hafnium oxide activated in vivo via standard radiation therapy. The company filed for CE Mark approval of NBTXR3 in 2016...